Pazopanib: therapeutic developments

Continuous daily dosing (CDD) of sunitinib (SU) in patients with metastatic soft tissue sarcomas (STS) other than GIST: Results of a phase II trial

(2017) M. L. Keohan et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeted therapy in renal cell carcinoma

(2010) Bhanu K Vakkalanka et al.   CURRENT OPINION IN UROLOGY

VEGF kinase inhibitors: how do they cause hypertension?

(2009) Pankaj Bhargava   AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY

Phase II study of sunitinib in men with advanced prostate cancer

(2009) M. Dror Michaelson et al.   ANNALS OF ONCOLOGY

Suppression and Regression of Choroidal Neovascularization by the Multitargeted Kinase Inhibitor Pazopanib

(2009) Kyoichi Takahashi   ARCHIVES OF OPHTHALMOLOGY

Vascular endothelial growth factor inhibition is not an effective therapeutic strategy for relapsed or refractory multiple myeloma: a phase 2 study of pazopanib (GW786034): Table 1

(2009) H. Miles Prince et al.   BLOOD

Hand-Foot Skin Reaction Increases with Cumulative Sorafenib Dose and with Combination Anti-Vascular Endothelial Growth Factor Therapy

(2009) N. S. Azad et al.   CLINICAL CANCER RESEARCH

Phase I Trial of Pazopanib in Patients with Advanced Cancer

(2009) H. I. Hurwitz et al.   CLINICAL CANCER RESEARCH

Survival After Second Primary Neoplasms of the Brain or Spinal Cord in Survivors of Childhood Cancer: Results From the British Childhood Cancer Survivor Study

(2009) Aliki J. Taylor et al.   JOURNAL OF CLINICAL ONCOLOGY

Multinational, Double-Blind, Phase III Study of Prednisone and Either Satraplatin or Placebo in Patients With Castrate-Refractory Prostate Cancer Progressing After Prior Chemotherapy: The SPARC Trial

(2009) Cora N. Sternberg et al.   JOURNAL OF CLINICAL ONCOLOGY

Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer–Soft Tissue and Bone Sarcoma Group (EORTC Study 62043)

(2009) Stefan Sleijfer et al.   JOURNAL OF CLINICAL ONCOLOGY

Analytical control of genotoxic impurities in the pazopanib hydrochloride manufacturing process

(2009) David Q. Liu et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Combined Inhibition of the VEGFR and EGFR Signaling Pathways in the Treatment of NSCLC

(2009) N. A. Pennell et al.   ONCOLOGIST

A Phase II Clinical Trial of Sorafenib in Androgen-Independent Prostate Cancer

(2008) W. L. Dahut et al.   CLINICAL CANCER RESEARCH

Emerging antiangiogenic treatments for gliomas – efficacy and safety issues

(2008) Jörg Dietrich et al.   CURRENT OPINION IN NEUROLOGY

Antiangiogenic therapy in malignant gliomas

(2008) Andrew D Norden et al.   CURRENT OPINION IN ONCOLOGY

Neovascular Age-Related Macular Degeneration

(2008) Aimee V Chappelow et al.   DRUGS

Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma

(2008) Guru Sonpavde et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Recurrent Priapism Related to Oxaliplatin Infusion

(2008) Antoine Adenis et al.   JOURNAL OF CLINICAL ONCOLOGY

Late Congestive Heart Failure After Hematopoietic Cell Transplantation

(2008) Saro H. Armenian et al.   JOURNAL OF CLINICAL ONCOLOGY

Discovery of 5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a Novel and Potent Vascular Endothelial Growth Factor Receptor Inhibitor†

(2008) Philip A. Harris et al.   JOURNAL OF MEDICINAL CHEMISTRY

Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib

(2008) S. E. Rosenbaum et al.   SUPPORTIVE CARE IN CANCER